Cerebral Atrophy and Convulsive Seizures after Recovery from Cerebral Edema and Coma in a Patient with Fulminant Hepatitis B

Suguru Honda*, Akira Taniguchi, Katsumasa Murai and Shigeki Kuzuhara

Abstract

We report a 48-year-old woman who developed convulsive seizures and cerebral atrophy after recovery from fulminant hepatitis B with coma and cerebral edema at the acute stage. Neurological disturbances and cerebral signs are rare sequelae of fulminant hepatic failure (FHF); only a few cases have reported in the literature. Cortical laminar necrosis secondary to cerebral edema or delayed neuronal death due to toxic substances may have caused delayed brain atrophy and epileptogenesis.

Key words: fulminant hepatic failure, neurological complication, brain computed tomography, electroencephalography

Introduction

Viral hepatitis and drugs are major causes of fulminant hepatic failure (FHF). FHF occurs in less than 1% of patients with viral hepatitis, and the mortality rate is extremely high. However, the diseased liver is potentially reversible, and permanent neurological disturbances in those who survived FHF occur rarely. To our knowledge, there are only a few reported cases of FHF with cerebral edema and coma at acute stage and subsequent cerebral atrophy and neurological complications after recovery. We report a survivor of FHF due to hepatitis B with cerebral edema who later developed cerebral atrophy and convulsive seizures.

Case Report

A 48-year-old woman was admitted for jaundice and coma on August 25, 1992. She had been healthy until the admission and did not have past history of alcoholism, blood transfusion, or drug usage. Her blood pressure was 164/104 mmHg, pulse rate 120 bpm, and temperature 37.7°C. She was comatose without spontaneous motor activity and speech, and withdrew the extremities with deep painful stimuli (Glasgow Coma Scale score; eye opening 1, motor response 3, verbal response 1). Her pupils were isocoric and reacted sluggishly to light. Deep tendon reflexes of the lower extremities were hyperactive, and the Babinski sign was positive bilaterally.

Laboratory data on admission indicated severe hepatic failure as follows; AST 2,549 IU/l, ALT 6,310 IU/l, total bilirubin 9.5 mg/dl, blood sugar 87 mg/dl, and ammonia 200 μmol/l (normal 3–40 μmol/l). IgM HBc antibody was positive. Brain computed tomography (CT) on admission showed findings indicative of severe diffuse cerebral edema, including loss of cortical sulci, low density of the white matter, and narrowing of the lateral and third cerebral ventricles (Fig. 1A). Electroencephalography (EEG) showed periodic synchronous discharges (PSD) on a low voltage background activity in all leads (Fig. 2).

Though the cause of infection was not clarified, a tentative diagnosis of FHF due to hepatitis B was made, and an intensive therapy with intravenous glucagon and insulin in combination with plasma exchange transfusion was started. Convulsive jerks occurred in the extremities and face several times a day, and they were controlled with repeated intravenous injections of 5 mg diazepam. On the 2nd hospital day, the liver function improved markedly; AST 234 IU/l, ALT 874 IU/l, total bilirubin 5.2 mg/dl, blood sugar 256 mg/dl, ammonia 100 μmol/l. Massive fresh-frozen plasma (FFP) was administered since cutaneous purpura had appeared. Her condition and laboratory data improved gradually. She finally recovered from FHF on the 20th day, and the serum ammonia level decreased to 44 μmol/l.

She had been well until the 32nd day when she suddenly had a generalized convulsive seizure with loss of consciousness which lasted for 20 minutes. Brain CT revealed marked
Figure 1. Follow up Brain CTs. (A) At the acute stage (August 28, 1992), there is marked cerebral edema with low density of white matter, narrowing of the lateral ventricles, and disappearance of the cortical sulci. (B) At the recovery from the coma (September 30, 1992), cerebral edema is markedly improved. (C) Marked cerebral atrophy is evident 5 years after the onset (December 24, 1997).
Cerebral Atrophy after Fulminant Hepatitis B

Figure 2. EEG during coma shows high voltage synchronous bursts on the low voltage background activities.

improvement of cerebral edema (Fig. 1B). Brain magnetic resonance imaging (MRI) on October 16, 1992 showed no findings indicative of laminar necrosis, borderzone infarction, or degeneration of globus pallidus.

A daily dose of 1,200 mg valproic acid and 1,000 mg primidone relieved the convulsive seizures. On December 17, 1997, she was readmitted for poor control of convulsive seizures. Neurological examination revealed hyperactive deep tendon reflexes and a positive Babinski sign on the left side. She complained of difficulties in mental concentration, and her short time memory was slightly disturbed. Verbal intelligence quotient (VIQ) was 67, and performance intelligence quotient (PIQ) 51, on the Wechsler Adult Intelligence Scale-revised (WAIS-R). Calculation and digit retention were markedly disturbed. Laboratory data including liver functions, serum ammonia level, blood gas, cerebrospinal fluid were within normal limit, and serum levels of valproic acid and primidone were within therapeutic concentrations.

Brain CT (Fig. 1C) as well as brain MRI demonstrated moderate cerebral cortical atrophy with enlargement of the third and lateral ventricles. An interictal single photon emission computed tomography (SPECT) with $^{123}$I-IMP revealed a marked decrease in the blood flow of the left temporo-occipital lobe. EEG showed basic activities of 9Hz $\alpha$ waves without epileptic discharges. A daily oral dose of 10 mg diazepam markedly reduced convulsive seizures.

Discussion

Cerebral edema, one of the major complications of FHF (1–4) causes death in 60 to 70% of FHF patients (5–7). Neuropsychiatric disturbances of survivors are rare since FHF and cerebral edema are usually reversible. Fiasse et al (8) reported a patient who survived FHF by exchange transfusion, and who had developed aphasia and acalculia. Tubbs et al (9) reported persistent psychiatric disturbances, and atrophy of the cerebral cortex and optic nerve on brain CT in a man who had survived FHF of unknown etiology. Toda et al (10) reported a survivor of FHF after blood transfusion, who had developed epileptic attacks, character changes, mental deterioration, and generalized brain atrophy on brain CT. In the present case, brain CT revealed marked swelling of the brain indicative of severe cerebral edema during coma at the acute stage, and marked cerebral atrophy five years after recovery.

Pathogenesis of cerebral edema in FHF remains unclarified. As to the production of cerebral edema, two hypotheses have been proposed. One is vasogenic mechanism which refers to a direct leakage of water into the brain tissue by disruption of the blood-brain barrier, and the other is cytotoxic mechanism which refers to an increase in water uptake into the brain tissue by cellular alterations (3, 11).

The mechanism of cerebral atrophy secondary to cerebral edema, and epileptogenesis in FHF is probably multifactorial. At the acute stage of FHF, she had no episodes of respiratory failure or shock which could cause hypoxia and subsequent cerebral atrophy. At the chronic stage when convulsive seizures occurred, hypoxemia and hyperammonemia were absent. Either toxic substances during hepatic failure or ischemia secondary to cerebral edema, or both can damage the brain tissue, and result in cerebral atrophy at the chronic stage. According to Kato et al (12), brain swelling in FHF is usually caused by cytotoxic edema, and hypoxia and hemorrhages secondary to brain swelling may also be noted. In the present case, the brain MRI at the acute stage showed no findings indicative of laminar necrosis, borderzone infarction, or degeneration of globus pallidus. However, low voltage slow background activities and PSD on EEG indicated diffuse severe damage of the cerebral cortex. Despite the absence of neuroimaging evidence, either cortical laminar necrosis or delayed neuronal death remains a possible cause of brain atrophy and epileptogenesis at the chronic stage.

More attention must be paid to the neurological complications of the survivors of FHF since with the recent development of new therapies for FHF more and more FHF patients have been cured.
Aknowledgements: We thank Dr. Katsuya Shiraki, Dr. Takashi Tanigawa, and Prof. Dr. Takeshi Nakano (First Department of Internal Medicine, Mie University, Japan) for their help and advice in preparing the manuscript.

References